Nuvig Therapeutics has closed a $161 million Series B financing and announced plans to progress to Phase II development with its immunomodulator for inflammatory autoimmune diseases. The financing was co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities (formerly Cowen Healthcare Investments), and Norwest Venture Partners. … Read More
Discover the groundbreaking findings from a study on bispecific T cell engagers conducted by The Jackson Laboratory. This case study delves into the tools available for assessing cytokine release and tumour growth inhibition. Explore the implications of donor-specific responses and how this knowledge can optimise the development of immunomodulatory therapeutics. Read More
Discover the groundbreaking findings from a study on bispecific T-cell engagers conducted by The Jackson Laboratory. This case study delves into the tools available for assessing cytokine release and tumour growth inhibition. Explore the implications of donor-specific responses and how this knowledge can optimise the development of immunomodulatory therapeutics. What… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. DDW’s Diana Spencer has selected five stand-out news headlines this week, which all relate to immunotherapy… Read More
News round-up for 1-5 May by DDW Digital Content Editor Diana Spencer. My five stand-out news headlines this week all relate to immunotherapy or immunomodulatory therapies for cancer, particularly advances in our understanding of how other factors in the body, i.e., vitamin D levels and the… Read More
Poolbeg Pharma, an infectious disease-focused biopharmaceutical company, has announced data from the bacterial lipopolysaccharide (‘LPS’) human challenge trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the unmet medical need arising from severe influenza and other acute inflammatory conditions. POLB 001… Read More
